Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Model-Supported Development of CS-8635: A Fixed-Dose Combination of Olmesartan, Amlodipine, and Hydrochlorothiazide.

Song S, Carrothers TJ, Moore H, Green M, Miller R, Rohatagi S, Lee J, Wang A, Melino M, Patel M, Heyrman R, Salazar DE.

Clin Pharmacol Drug Dev. 2013 Apr;2(2):103-12. doi: 10.1002/cpdd.17. Epub 2013 Mar 16.

PMID:
27121665
2.

Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.

Rohatagi S, Mendell J, Kastrissios H, Green M, Shi M, Patel I, Salazar DE.

Thromb Haemost. 2012 Nov;108(5):887-95. doi: 10.1160/TH12-03-0184. Epub 2012 Sep 26.

PMID:
23014669
3.

Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension.

Wells TG, Blowey DL, Sullivan JE, Blumer J, Sherbotie JR, Song S, Rohatagi S, Heyrman R, Salazar DE.

Paediatr Drugs. 2012 Dec 1;14(6):401-9. doi: 10.2165/11631450-000000000-00000.

PMID:
22880942
4.

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation.

Salazar DE, Mendell J, Kastrissios H, Green M, Carrothers TJ, Song S, Patel I, Bocanegra TS, Antman EM, Giugliano RP, Kunitada S, Dornseif B, Shi M, Tachibana M, Zhou S, Rohatagi S.

Thromb Haemost. 2012 May;107(5):925-36. doi: 10.1160/TH11-08-0566. Epub 2012 Mar 8.

PMID:
22398655
5.

The use of modeling and simulation to guide clinical development of olmesartan medoxomil in pediatric subjects.

Salazar DE, Song SH, Shi J, Rohatagi S, Heyrman R, Wada DR, Carrothers TJ.

Clin Pharmacol Ther. 2012 Feb;91(2):250-6. doi: 10.1038/clpt.2011.220. Epub 2011 Dec 28.

PMID:
22205195
6.

Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy.

Riesmeyer JS, Salazar DE, Weerakkody GJ, Ni L, Wrishko RE, Ernest CS 2nd, Luo J, Li YG, Small DS, Rohatagi S, Macias WL.

J Clin Pharmacol. 2012 Jun;52(6):789-97. doi: 10.1177/0091270011406280. Epub 2011 May 31.

PMID:
21628601
7.

Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.

Small DS, Farid NA, Payne CD, Konkoy CS, Jakubowski JA, Winters KJ, Salazar DE.

Clin Pharmacokinet. 2010 Dec;49(12):777-98. doi: 10.2165/11537820-000000000-00000. Review.

PMID:
21053990
8.

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.

Small DS, Payne CD, Kothare P, Yuen E, Natanegara F, Teng Loh M, Jakubowski JA, Richard Lachno D, Li YG, Winters KJ, Farid NA, Ni L, Salazar DE, Tomlin M, Kelly R.

Clin Ther. 2010 Feb;32(2):365-79. doi: 10.1016/j.clinthera.2010.02.015.

PMID:
20206794
9.

Correlation of inhibition of platelet aggregation with cardiovascular and bleeding outcomes in acute coronary syndromes.

Wada R, Rohatagi S, Small D, Winters KJ, Salazar DE.

J Clin Pharmacol. 2010 Aug;50(8):904-13. doi: 10.1177/0091270009353606. Epub 2010 Feb 10.

PMID:
20147617
10.

The pharmacokinetics and pharmacodynamics of prasugrel in healthy Chinese, Japanese, and Korean subjects compared with healthy Caucasian subjects.

Small DS, Kothare P, Yuen E, Lachno DR, Li YG, Winters KJ, Farid NA, Ni L, Jakubowski JA, Salazar DE, Thieu VT, Payne CD.

Eur J Clin Pharmacol. 2010 Feb;66(2):127-35. doi: 10.1007/s00228-009-0737-1. Epub 2009 Nov 4.

PMID:
19888568
11.

Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide.

Brown KS, Armstrong IC, Wang A, Walker JR, Noveck RJ, Swearingen D, Allison M, Kissling JC, Kisicki J, Salazar DE.

J Clin Pharmacol. 2010 May;50(5):554-65. doi: 10.1177/0091270009349378. Epub 2009 Sep 29.

PMID:
19789374
12.

Quantitative structure-property relationships modeling to predict in vitro and in vivo binding of drugs to the bile sequestrant, colesevelam (Welchol).

Walker JR, Brown K, Rohatagi S, Bathala MS, Xu C, Wickremasingha PK, Salazar DE, Mager DE.

J Clin Pharmacol. 2009 Oct;49(10):1185-95. doi: 10.1177/0091270009340783.

PMID:
19783712
13.

Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease.

Small DS, Wrishko RE, Ernest CS 2nd, Ni L, Winters KJ, Farid NA, Li YG, Brandt JT, Salazar DE, Borel AG, Kles KA, Payne CD.

J Clin Pharm Ther. 2009 Oct;34(5):585-94. doi: 10.1111/j.1365-2710.2009.01068.x.

PMID:
19744014
14.

Pharmacokinetics and pharmacodynamics of prasugrel in subjects with moderate liver disease.

Small DS, Farid NA, Li YG, Ernest CS 2nd, Winters KJ, Salazar DE, Payne CD.

J Clin Pharm Ther. 2009 Oct;34(5):575-83. doi: 10.1111/j.1365-2710.2009.01067.x.

PMID:
19744013
15.

Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial.

Small DS, Wrishko RE, Ernest CS 2nd, Ni L, Winters KJ, Farid NA, Li YG, Salazar DE, Payne CD.

Drugs Aging. 2009;26(9):781-90. doi: 10.2165/11315780-000000000-00000.

PMID:
19728751
16.

An open-label study of aripiprazole: pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder.

Findling RL, Kauffman R, Sallee FR, Salazar DE, Sahasrabudhe V, Kollia G, Kornhauser DM, Vachharajani NN, Assuncao-Talbott S, Mallikaarjun S, Iwamoto T, McQuade RD, Boulton DW, Blumer J.

J Child Adolesc Psychopharmacol. 2009 Aug;19(4):431-9. doi: 10.1089/cap.2008.0111.

PMID:
19702495
17.

Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.

Wrishko RE, Ernest CS 2nd, Small DS, Li YG, Weerakkody GJ, Riesmeyer JR, Macias WL, Rohatagi S, Salazar DE, Antman EM, Wiviott SD, Braunwald E, Ni L.

J Clin Pharmacol. 2009 Aug;49(8):984-98. doi: 10.1177/0091270009337942. Epub 2009 Jun 22.

PMID:
19546250
18.

Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects.

Farid NA, Jakubowski JA, Payne CD, Li YG, Jin Y, Ernest II CS, Winters KJ, Brandt JT, Salazar DE, Small DS.

Curr Med Res Opin. 2009 Aug;25(8):1821-9. doi: 10.1185/03007990903018360.

PMID:
19530977
19.

Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects.

Farid NA, Small DS, Payne CD, Jakubowski JA, Brandt JT, Li YG, Ernest CS, Salazar DE, Konkoy CS, Winters KJ.

Pharmacotherapy. 2008 Dec;28(12):1483-94. doi: 10.1592/phco.28.12.1483.

PMID:
19025429
20.

Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.

Ernest CS 2nd, Small DS, Rohatagi S, Salazar DE, Wallentin L, Winters KJ, Wrishko RE.

J Pharmacokinet Pharmacodyn. 2008 Dec;35(6):593-618. doi: 10.1007/s10928-008-9103-7. Epub 2008 Nov 21.

PMID:
19023649
21.

Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination.

Rohatagi S, Lee J, Shenouda M, Haworth S, Bathala MS, Allison M, Rubets I, Heyrman R, Noveck R, Salazar DE.

J Clin Pharmacol. 2008 Nov;48(11):1309-22. doi: 10.1177/0091270008322176.

PMID:
18974285
22.

Model-based development of a PPARgamma agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs.

Rohatagi S, Carrothers TJ, Jin J, Jusko WJ, Khariton T, Walker J, Truitt K, Salazar DE.

J Clin Pharmacol. 2008 Dec;48(12):1420-9. doi: 10.1177/0091270008323260. Epub 2008 Oct 20.

PMID:
18936283
23.

Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.

Small DS, Farid NA, Li YG, Ernest CS 2nd, Payne CD, Salazar DE, Winters KJ.

Curr Med Res Opin. 2008 Aug;24(8):2251-7. doi: 10.1185/03007990802205985.

PMID:
18786302
24.

Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects.

Payne CD, Li YG, Brandt JT, Jakubowski JA, Small DS, Farid NA, Salazar DE, Winters KJ.

Platelets. 2008 Jun;19(4):275-81. doi: 10.1080/09537100801891640.

PMID:
18569863
25.

Pain relief model for a COX-2 inhibitor in patients with postoperative dental pain.

Rohatagi S, Kastrissios H, Sasahara K, Truitt K, Moberly JB, Wada R, Salazar DE.

Br J Clin Pharmacol. 2008 Jul;66(1):60-70. doi: 10.1111/j.1365-2125.2008.03175.x. Epub 2008 Jun 3.

26.

Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel.

Small DS, Farid NA, Payne CD, Weerakkody GJ, Li YG, Brandt JT, Salazar DE, Winters KJ.

J Clin Pharmacol. 2008 Apr;48(4):475-84. doi: 10.1177/0091270008315310. Epub 2008 Feb 26.

PMID:
18303127
27.

The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration.

Jakubowski JA, Payne CD, Li YG, Brandt JT, Small DS, Farid NA, Salazar DE, Winters KJ.

Thromb Haemost. 2008 Feb;99(2):409-15. doi: 10.1160/TH07-09-0575.

PMID:
18278193
28.

A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry.

Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ.

Thromb Haemost. 2008 Jan;99(1):215-22. doi: 10.1160/TH07-09-0555.

PMID:
18217157
29.

Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans.

Farid NA, Payne CD, Ernest CS 2nd, Li YG, Winters KJ, Salazar DE, Small DS.

J Clin Pharmacol. 2008 Jan;48(1):53-9.

PMID:
18094219
30.

Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.

Payne CD, Li YG, Small DS, Ernest CS 2nd, Farid NA, Jakubowski JA, Brandt JT, Salazar DE, Winters KJ.

J Cardiovasc Pharmacol. 2007 Nov;50(5):555-62.

PMID:
18030066
31.

Pharmacokinetics of aripiprazole and concomitant carbamazepine.

Citrome L, Macher JP, Salazar DE, Mallikaarjun S, Boulton DW.

J Clin Psychopharmacol. 2007 Jun;27(3):279-83.

PMID:
17502775
32.

Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.

Farid NA, Payne CD, Small DS, Winters KJ, Ernest CS 2nd, Brandt JT, Darstein C, Jakubowski JA, Salazar DE.

Clin Pharmacol Ther. 2007 May;81(5):735-41. Epub 2007 Mar 14.

PMID:
17361128
33.

Pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range.

Dockens RC, Salazar DE, Fulmor IE, Wehling M, Arnold ME, Croop R.

J Clin Pharmacol. 2006 Nov;46(11):1308-12.

PMID:
17050795
34.

Effect of repeated oral administrations of the oral adsorbent AST-120 on serum creatinine and other markers of renal function. A randomized controlled study in patients with chronic kidney disease.

Marier JF, Lee J, Kambhampati SR, Galitz L, Vargas R, Moberly J, Salazar DE.

Am J Nephrol. 2006;26(2):136-41. Epub 2006 Mar 22.

PMID:
16549905
35.

The effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects.

Marier JF, Guilbaud R, Kambhampati SR, Mathew P, Moberly J, Lee J, Salazar DE.

J Clin Pharmacol. 2006 Mar;46(3):310-20.

PMID:
16490807
36.

Pharmacokinetics of aripiprazole and concomitant lithium and valproate.

Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S.

J Clin Pharmacol. 2005 Jan;45(1):89-93.

PMID:
15601809
37.

Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.

Mallikaarjun S, Salazar DE, Bramer SL.

J Clin Pharmacol. 2004 Feb;44(2):179-87.

PMID:
14747427
38.

Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa.

Frackiewicz EJ, Jhee SS, Shiovitz TM, Webster J, Topham C, Dockens RC, Whigan D, Salazar DE, Cutler NR.

Ann Pharmacother. 2002 Feb;36(2):225-30.

PMID:
11847938
39.

Pharmacokinetics and tolerability of buspirone during oral administration to children and adolescents with anxiety disorder and normal healthy adults.

Salazar DE, Frackiewicz EJ, Dockens R, Kollia G, Fulmor IE, Tigel PD, Uderman HD, Shiovitz TM, Sramek JJ, Cutler NR.

J Clin Pharmacol. 2001 Dec;41(12):1351-8.

PMID:
11762563
40.

Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation.

Abernethy DR, Barbey JT, Franc J, Brown KS, Feirrera I, Ford N, Salazar DE.

Clin Pharmacol Ther. 2001 Mar;69(3):96-103.

PMID:
11240972
41.

Carbamazepine-nefazodone interaction in healthy subjects.

Laroudie C, Salazar DE, Cosson JP, Cheuvart B, Istin B, Girault J, Ingrand I, Decourt JP.

J Clin Psychopharmacol. 2000 Feb;20(1):46-53.

PMID:
10653208
42.

Central nervous system pharmacokinetics of psychiatric drugs.

Salazar DE, Fischman AJ.

J Clin Pharmacol. 1999 Aug;39(S1):10S-12S. No abstract available.

PMID:
10434241
43.

Pharmacokinetics and pharmacodynamics of avitriptan during intravenous administration in healthy subjects.

Sharma A, Jusko WJ, Fulmor IE, Norton J, Uderman HD, Salazar DE.

J Clin Pharmacol. 1999 Jul;39(7):685-94.

PMID:
10392323
44.
45.

Pharmacokinetic evaluation of co-administration of nefazodone and lithium in healthy subjects.

Laroudie C, Salazar DE, Cosson JP, Cheuvart B, Istin B, Girault J, Ingrand I, Decourt JP.

Eur J Clin Pharmacol. 1999 Feb;54(12):923-8.

PMID:
10192752
46.

Pharmacokinetics and pharmacodynamics of avitriptan in patients with migraine after oral dosing.

Cutler NR, Salazar DE, Jhee SS, Fulmor IE, Ford N, Smith RA, Sramek JJ.

Headache. 1998 Jun;38(6):446-52.

PMID:
9664749
47.

A pharmacokinetic-pharmacodynamic model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects.

Salazar DE, Much DR, Nichola PS, Seibold JR, Shindler D, Slugg PH.

J Clin Pharmacol. 1997 Sep;37(9):799-809.

PMID:
9549633
48.

Monitoring of acute migraine attacks: placebo response and safety data.

Jhee SS, Salazar DE, Ford NF, Fulmor IE, Sramek JJ, Cutler NR.

Headache. 1998 Jan;38(1):35-8.

PMID:
9505001
49.

Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography.

Christian BT, Livni E, Babich JW, Alpert NM, Dischino DD, Ruediger E, Salazar DE, Ford NF, Fischman AJ.

J Pharmacol Exp Ther. 1996 Oct;279(1):325-31.

PMID:
8859010
50.

Coadministration of nefazodone and benzodiazepines: IV. A pharmacokinetic interaction study with lorazepam.

Greene DS, Salazar DE, Dockens RC, Kroboth P, Barbhaiya RH.

J Clin Psychopharmacol. 1995 Dec;15(6):409-16.

PMID:
8748429

Supplemental Content

Loading ...
Support Center